# OnCo record allo-hct-gvhd-prophylaxis (protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/protocols/allo-hct-gvhd-prophylaxis/>
  a schema:MedicalGuideline ;
  onco:kind "protocol" ;
  schema:identifier "allo-hct-gvhd-prophylaxis" ;
  schema:name "GVHD prophylaxis after allogeneic stem cell transplant: choosing the regimen"@en ;
  schema:alternateName "GvHD prophylaxis regimen"@en, "post-transplant cyclophosphamide"@en, "PTCy"@en, "ATG prophylaxis"@en, "calcineurin inhibitor and methotrexate"@en, "tacrolimus and mycophenolate"@en ;
  schema:description "After a donor transplant, everyone takes medicines to stop the donor's immune cells attacking their body (graft-versus-host disease). The combination depends on the donor, the pre-transplant treatment and whether the cells came from blood or marrow. Newer combinations reduce graft-versus-host disease; in the main trial they did not lengthen life, and each has its own side effects."@en ;
  schema:url <https://onco.cc/protocols/allo-hct-gvhd-prophylaxis/> ;
  schema:dateModified "2026-11-11"^^xsd:date ;
  onco:tag "protocol", "cell-therapy", "transplant", "gvhd" ;
  onco:related <https://onco.cc/technologies/gvhd-ruxolitinib-steroid-refractory/> ;
  onco:technologies <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/gvhd-prophylaxis/> ;
  onco:drugs <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/sirolimus/> ;
  onco:terms <https://onco.cc/terms/gvhd/>, <https://onco.cc/terms/conditioning-regimen/> .